The authors evaluated the efficacy, patterns of failure, and toxicity of stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical stage I non-small cell lung cancer (NSCLC) in a prospective clinical trial with 7 years of follow-up. Clinical staging was performed according to the seventh edition of the American Joint Committee on Cancer TNM staging system. METHODS: Eligible patients with histologically confirmed NSCLC of clinical stage I as determined using positron emission tomography staging were treated with SABR (50 grays in 4 fractions). The primary endpoint was progression-free survival. Patients were followed with computed tomography and/or positron emission tomography/computed tomography every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually thereafter. RESULTS: A total of 65 patients were eligible for analysis. The median age of the patients was 71 years, and the median follow-up was 7.2 years. A total of 18 patients (27.7%) developed disease recurrence at a median of 14.5 months (range, 4.3-71.5 months) after SABR. Estimated incidences of local, regional, and distant disease recurrence using competing risk analysis were 8.1%, 10.9%, and 11.0%, respectively, at 5 years and 8.1%, 13.6%, and 13.8%, respectively, at 7 years. A second primary lung carcinoma developed in 12 patients (18.5%) at a median of 35 months (range, 5-67 months) after SABR. Estimated 5-year and 7-year progression-free survival rates were 49.5% and 38.2%, respectively; the corresponding overall survival rates were 55.7% and 47.5%, respectively. Three patients (4.6%) experienced grade 3 treatment-related adverse events. No patients developed grade 4 or 5 adverse events (toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]). CONCLUSIONS: With long-term follow-up, the results of the current prospective study demonstrated outstanding local control and low toxicity after SABR in patients with clinical stage I NSCLC. Regional disease recurrence and distant metastases were the dominant manifestations of failure. Surveillance for second primary lung carcinoma is recommended. Cancer 2017;123:3031-9. V C 2017 American Cancer Society.
INTRODUCTION
Image-guided stereotactic ablative radiotherapy (SABR), also called stereotactic body radiotherapy, as a noninvasive treatment has become the standard of care for patients with medically inoperable early-stage, non-small cell lung cancer (NSCLC). Population-based retrospective studies and a recent pooled analysis of 2 prospective randomized trials have indicated that SABR has effectiveness comparable to that of surgery for this population, with reported 3-year overall survival (OS) rates of 48% to 91% and local control rates of 85% to 96%. [1] [2] [3] [4] Nonetheless, the efficacy, patterns of failure, and toxicity reported with SABR were based for the most part on relatively short-term follow-up. Currently, to the best of our knowledge, robust long-term outcome data at follow-ups >5 years are limited. As increasing numbers of early-stage lung cancers are being detected worldwide and the effectiveness of SABR realized, SABR is gradually being applied to patients with inoperable, borderline operable, or even operable early-stage NSCLC who have a longer life expectancy. Thus, long-term data regarding the outcomes of SABR are needed urgently to strengthen confidence in its use.
We initiated a prospective clinical trial of SABR early in 2005. The objectives of this study were to assess the therapeutic effectiveness and toxicity of SABR for patients with medically inoperable stage I NSCLC. To the best of our knowledge, this is the first report of the study and the only one in the literature regarding the patterns of failure, prognosis, and toxicity after a median follow-up of 7 years. We also assessed the literature regarding the use of SABR versus surgery for patients with early-stage NSCLC.
MATERIALS AND METHODS

Patients and Study Design
From November 2005 to March 2013, a total of 73 patients with histologically confirmed NSCLC were prospectively enrolled in this trial. Among 8 patients removed from the final analysis, 4 patients received conventional radiotherapy due to normal tissue constraints and 4 patients were lost to follow-up. The current study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center, and all patients provided written informed consent to participate.
Inclusion criteria were a diagnosis of medically inoperable clinical stage IA (T1N0M0: tumor size <3 cm [T1], no regional lymph node metastasis [N0] , and no distant metastasis [M0]) or stage IB (T2aN0M0: tumor measuring >3 cm but 5 cm in greatest dimension [T2a]) histologically confirmed NSCLC. Clinical staging was performed according to the seventh edition of the American Joint Committee on Cancer TNM staging system. Patients with operable disease who elected to undergo SABR also were eligible. For patients with a prior history of lung cancer, patients were required to be free of lung cancer for >5 years for the same histology or >2 years for a different histology to reduce the impact of prior disease and treatment on the prognosis and toxicity of SABR. Patients were clinically staged using computed tomography (CT) and [ 18 F]fludeoxyglucose ( 18 F-FDG)-positron emission-CT (PET/CT) within 3 months before undergoing SABR. Patients with hilar or mediastinal lymph nodes measuring 1 cm and no abnormal hilar or mediastinal uptake on PET were considered to have N0 disease. Endobronchial ultrasound (EBUS) was performed for patients with hilar or mediastinal lymph nodes measuring >1 cm on CT or an abnormal PET scan (including high avidity and suspicious but nondiagnostic uptake). Specifically, an abnormal lymph node maximum standardized uptake value (SUVmax) that was higher than the SUVs of the mediastinal blood pool was used as a reference to define abnormal uptake, but the final decision regarding EBUS was made based on the clinical judgment of the treating physicians and the radiologists regarding the PET findings and CT criteria as defined above.
Stereotactic Ablative Radiotherapy
All patients underwent 4-dimensional CT-based simulation, and respiratory gating was considered if the tumor moved >1 cm. Approximately 15% of patients were treated with respiratory gating using video feedbackdriven voluntary deep inspiration breath hold. Internal macroscopic (gross) target volume (IGTV) was contoured according to maximal intensity projection and edited at different phases. Image-guided SABR for a total dose of 50 grays (Gy) in 4 fractions was prescribed to the planning target volume (PTV). Unmodulated (3-dimensional conformal) or intensity-modulated radiotherapy SABR plans were optimized by using 6 to 12 coplanar or noncoplanar 6-megavolt photon beams. The prescribed isodose line was required to cover >95% of the PTV and 100% of the IGTV. Details regarding SABR simulation, planning, treatment delivery, and dose volume constraints were described previously.
5,6
Follow-Up Evaluations
The primary endpoint was progression-free survival (PFS). Patients underwent a chest CT scan every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually. PET/CT was required between 2 months to 6 months after the completion of SABR; subsequent PET scanning was indicated if there was any sign of recurrent disease. Local disease recurrence (LR) was defined as CT evidence of progressive soft tissue abnormalities in the same lobe that corresponded to avid (SUVmax >5) areas on PET/CT images obtained >6 months after SABR. Biopsy was strongly recommended to confirm a suspected disease recurrence. LR was classified as an in-field disease recurrence (occurring within the area inside the PTV), involved lobe failure (out-of-field disease recurrence in the same lobe), or marginal failure (a recurrent lesion located within 1 cm in any direction around the PTV). Regional disease recurrence (RR) was defined as any intrathoracic lymph node recurrence outside of the PTV. Distant metastasis (DM) was defined as any disease recurrence in a different lobe or any failure outside the chest.
A second primary lung carcinoma (SPLC) after SABR was defined using the modified criteria of Martini and Melamed 7 : a new tumor with a different histological type/subtype or molecular genomic characteristics from
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Cancer the first tumor or a new tumor with the same histology in a different lobe or lung if 1) it occurred at a tumor-free interval of >2 years and without any evidence of carcinoma in the lymphatics and extrapulmonary metastases and 2) it was reviewed by a multidisciplinary tumor team including treating physicians, a pathologist, and a radiologist for its pathological morphology, radiological features, tumor location, previous cancer history, and imaging features and was verified by follow-up outcome with no tumor recurrence after definitive treatment for a minimum of 1 year of follow-up.
Statistical Analysis
PFS events as the primary endpoints, including any disease recurrence (LR, RR, and DM) and death, were calculated from the beginning date of SABR to the date of the first disease recurrence or death (for patients who were not known to have developed a disease recurrence but had died). The date of disease recurrence was the date of the first CT or PET/CT image that demonstrated abnormalities. SPLC was not considered as a PFS event. OS analysis was calculated from the beginning date of SABR to the date of death or last follow-up.
All statistical analyses were performed using SPSS statistical software (version 21.0; IBM Corporation, Armonk, NY) and R statistical software (version 3.1.2) using the cmprsk_v2.2-7 and survival_v2.38-1 packages (R Foundation, Vienna, Austria). The median follow-up was computed using the reverse Kaplan-Meier method. The OS curve was determined using the Kaplan-Meier method. In the presence of competing risks (death) when performing survival analyses for any disease recurrence, an alternative cumulative incidence competing risk method was used to overcome the overestimated probabilities of disease recurrence. 8 All significance tests were 2-tailed with a P value <.05 considered to be statistically significant.
This trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier NCT00489008).
RESULTS
Patient Characteristics
A total of 65 patients were eligible for analysis ( Fig. 1) ( Table 1 ). Eighteen patients (27.7%) underwent EBUS staging, and 14 patients (21.5%) were considered to have potentially operable disease. EBUS was performed in 6 patients with PET demonstrating FDG-avid lymph nodes; in 6 patients, CT results demonstrated a large short axis. A prior history of lung cancer was identified in 13 patients (20.0%): 7 patients (10.8%) had had the same histology previously with a tumor-free duration of >5 years and 6 patients (9.2%) had had a different histology previously with a tumor-free duration of >2 years. Four of the 13 patients had received irradiation before SABR (1 had SABR and 3 had undergone conventional thoracic radiotherapy). A prior history of a malignancy other than lung cancer was identified in 12 patients (18.5%).
Patterns of Failure, Salvage Treatment, and Survival
At a median follow-up of 7.2 years (interquartile range, 4.6-8.3 years), 18 patients (27.7%) had developed disease recurrence. The minimum and maximum follow-up times for alive patients were 3.1 years and 10.2 years, respectively. The initial disease recurrence manifested as LR in 5 patients (7.7%), RR in 8 patients (12.3%), and DM in 8 patients (12.3%); 2 patients experienced simultaneous failure (Table 1) . Of the 5 patients who had LR as their first event, all patients underwent PET imaging with a median SUVmax of 7.2 (range, 5.0-12.2), and 4 patients had histological confirmation of disease recurrence. Furthermore, 3 patients had their disease recurrence classified as an in-field recurrence, 1 patient's recurrence was classified as an out-of-field recurrence, and 1 patient's recurrence was classified as a marginal recurrence.
The median time to any initial disease recurrence was 14.5 months (range, 4.3-71.5 months). Of note, 2 of 8 patients (25.0%) had a very short time to RR (4.3 months and 5.2 months, respectively) and 4 of these 8 patients (50.0%) experienced DM at a short interval of approximately 6 months after undergoing SABR. For the 8 patients who had an initial DM, the most common site was pulmonary (50.0%); other sites were the bone, liver, and distant lymph nodes. Estimated cumulative 5-year rates of LR, RR, and DM using competing risk analysis were 8.1%, 10.9%, and 11.0%, respectively. Corresponding 7-year incidence rates increased to 8.1%, 13.6%, and 13.8%, respectively ( Fig. 2A) ( Table 2 ).
The estimated 5-year and 7-year PFS rates were 49.5% and 38.2%, respectively, and those for OS were 55.7% and 47.5%, respectively ( Fig. 2B) 10 ] to 95% of the PTV <a median value of 113.6 Gy; mean PTV BED dose < median value of 135 Gy), which might be because the dose was prescribed to an inappropriate isodose line. It should be noted that for 2 patients, a lesion located within the same lobe that had undergone SABR was found on biopsy to be a second lung malignancy with different histology. Because of the small number of events, we were unable to draw conclusions regarding risk factors for any form of disease recurrence. 
months).
Toxicity
The most common adverse effects were dermatitis, radiation pneumonitis, and chest wall pain ( 
DISCUSSION
In the current prospective phase 2 study, which was conducted >10 years ago to investigate the efficacy of SABR for patients with clinical stage I NSCLC and which has a median follow-up of >7 years, we found outstanding outcomes with low rates of LR, RR, and DM at 5 years (8.1%, 10.9%, and 11.0%, respectively). It is interesting to note that the 7-year estimated RR and DM rates increased slightly, indicating that a recurrence event could occur after 5 years. With respect to LR, it has been recognized only recently that a smaller IGTV and a higher radiation dose delivered to the PTV are associated with better local control, which was supported by 5 LRs reported in the current study. 9 The DM rate in the current study appears to be lower than previously reported results. This is likely because all patients had a pathological diagnosis and rigorous PET staging before undergoing SABR, and the majority of patients with high-risk features of lymph node involvement underwent an EBUS procedure before study enrollment. [10] [11] [12] [13] [14] [15] [16] [17] Furthermore, most patients developed intrathoracic lesions that were verified with biopsy, and some were found to be secondary lung malignancies. This routine biopsy of suspected recurrent lesions in the lung was missing in the majority of other SABR studies. Therefore, it is helpful to have accurate staging performed before SABR and histological testing to differentiate a second primary lesion from a disease recurrence. In addition, SPLC developed in approximately 18.5% patients during the 7-year surveillance period. Given these data and published results, 18 ,19 a long duration of follow-up (>2 years) and routine surveillance after SABR, perhaps even longer than currently believed to be necessary, are important for detecting disease recurrence, including SPLC, which is a significant risk for all patients with lung cancer.
Notably, approximately one-third of patients in the current study with RR and/or DM developed the recurrence within 6 months of undergoing SABR. The short interval suggests the existence of an occult tumor before SABR was administered. Subclinical disease is difficult to detect by current image modalities, and therefore RR and DM remain the predominant patterns of failure. A more accurate method than PET/CT to detect occult tumor before SABR is performed should be explored. More important, treatments that are effective in eradicating occult metastases would alter the disease status and improve prognosis. A combination of an immunotherapeutic approach and SABR (termed "ISABR") recently has been proposed because there is evidence of synergy between immunotherapy and SABR, as well as evidence that immunotherapy works in the metastatic setting and may be best, in fact, at eliminating micrometastatic rather than bulky disease. [20] [21] [22] Thus, ISABR, a promising approach that is currently being investigated, may address both visible and occult disease, and further improve outcomes of SABR for patients with early-stage NSCLC.
In the current study, the actual incidence of developing an SPLC appeared to be relatively high. The historical estimated risk of SPLC is reported to range from 1% to 6% per person-year after surgical resection, and can increase slightly over time. 23, 24 The crude rate is reported to be between 3.2% and 15.3% with short followup, 1, 13, 18, 25 and its actuarial risk reaches 11.7% to 20% at 5 to 8 years after the patient undergoes initial surgery for NSCLC. 19, 26, 27 It is noteworthy that although SPLC is an undesirable occurrence, it often is highly curable, with few disease recurrences reported to occur after definitive treatment. In addition, approximately one-half of patients with only an LR or RR did not develop a subsequent disease recurrence after undergoing salvage treatment. Thus, SPLC is a concern for long-term follow-up, and close surveillance will help to identify a new lesion/disease recurrence at an early stage when it can be considered for curative local therapy to obtain a better prognosis.
To our knowledge to date, the role of SABR in the treatment of patients with operable stage I NSCLC has been debated. 28 Table 4 outlines studies reporting outcomes after SABR or surgery for patients with early-stage NSCLC.
1-4,10-18,29-31 A pooled analysis of 2 randomized controlled trials indicated that SABR is comparable to lobectomy in terms of PFS, with improved OS at 3 years and a lower toxicity profile in patients with operable disease. 1 The limitations of this nonplanned, pooled analysis include a short follow-up and a small sample size from the 2 trials that were closed early due to poor accrual. However, when comparing the 2 modalities using nonrandomized studies, it should be noted that there are several pitfalls and potential biases that affect interpretation of the results. First, there are discrepancies regarding the definitions of LR, RR, and DM between studies examining the use of surgery and SABR, and even among different SABR studies. For example, in many surgery studies, failure in the ipsilateral hilum and mediastinum is defined as an RR, and failure in a contralateral lymph node is defined as a DM, 4, 13 whereas in the majority of SABR studies disease recurrence in an intrathoracic lymph node is regarded as an RR. Thus, the rate of RR may appear lower in surgical studies simply by virtue of definition. A second pitfall is that all patients who underwent SABR were staged clinically rather than pathologically, whereas the majority of patients treated with surgery underwent surgical lymph node sampling/dissection, which resulted in upstaging in 7.3% to approximately 35% of patients who were considered preoperatively to have early-stage disease. 2, 4, [29] [30] [31] Many patients with lymph node-positive and upstaged disease receive postoperative chemotherapy and/or radiotherapy, which improves outcomes, and/or these upstaged patients typically are excluded from outcome analyses that could be biased toward surgery. Third, even in some propensity-matched analyses, approximately one-half of patients treated with SABR were considered to have medically inoperable disease but nevertheless were matched with patients who received surgery despite the fact that some important baseline characteristics such as Eastern Cooperative Oncology Group performance status, pulmonary function, and pretreatment reliable lymph node evaluation were rarely matched. 3, 4 A fourth pitfall is that many surgical studies that reported locoregional disease recurrences reported them as actual percentages instead of estimated cumulative incidences with a time point that will be higher than the actual rate over long time.
One of the criticisms of SABR is that it does not include mediastinal lymph node dissection, which raises the concern of lower locoregional control. However, to our knowledge, it is not quite clear whether lymph node dissection is therapeutic or diagnostic. In the current study, we estimated the probabilities of disease recurrence using a competing risk model with 7 years of follow-up, which to our knowledge is the longest among all published literature to date. The results demonstrated that although the locoregional disease recurrence rate after SABR was on the high end (12.3% and 17.4%, respectively, at 3 years and 5 years) it still fell within the range of that reported with surgery (Table 4) . However, the results reported herein for DM, PFS, and even OS are not only within the range but also at the average rate of those observed with surgery (except for data from Japan), even though the majority of patients in the current study were older and had medically inoperable disease. When patients who received SABR and for whom dates of death were available but who did not return for imaging and a follow-up visit were included, the 5-year and 7-year OS rates were 54.3% and 46.4%, respectively. However, we would like to point out that the tumor size in the current study was relatively small (4 cm) and that the majority of patients (95%) were classified with T1 tumors (those measuring 3 cm), which could contribute to the better outcomes as demonstrated in other studies. 17 Again, larger prospective randomized trials comparing the 2 modalities are needed and currently ongoing.
To the best of our knowledge, the current prospective study represents the first to investigate the use of SABR for patients with early-stage NSCLC with the longest follow-up reported to date of 7 years. The results demonstrated outstanding OS with rates of locoregional and distant control for SABR that were comparable to those for surgery but with a lower toxicity. LR needs to be reviewed carefully to rule out SPLC. RR and DM remain the dominant failures, indicating that staging prior to SABR is important, and the combination of SABR with systemic therapy such as immunotherapy should be explored to improve patient outcomes. Development of a second malignancy remains one of the most common issues with longer follow-up, which again is consistent with surgical data. Therefore, close posttherapeutic surveillance scanning and aggressive salvage treatment are crucial because many cases of recurrent disease and SPLC are highly curable.
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